CXCR7 antibody [C1C2], Internal
GTX100027
ApplicationsFlow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ELISA, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetACKR3
Overview
- SupplierGeneTex
- Product NameCXCR7 antibody [C1C2], Internal
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsFlow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ELISA, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration0.14 mg/ml
- ConjugateUnconjugated
- Gene ID57007
- Target nameACKR3
- Target descriptionatypical chemokine receptor 3
- Target synonymsCMKOR1, CXC-R7, CXCR-7, CXCR7, GPR159, RDC-1, RDC1, atypical chemokine receptor 3, C-X-C chemokine receptor type 7, G protein-coupled receptor, G-protein coupled receptor 159, G-protein coupled receptor RDC1 homolog, chemokine (C-X-C motif) receptor 7, chemokine orphan receptor 1
- HostRabbit
- IsotypeIgG
- Protein IDP25106
- Protein NameAtypical chemokine receptor 3
- Scientific DescriptionThis gene encodes a member of the G-protein coupled receptor family. Although this protein was earlier thought to be a receptor for vasoactive intestinal peptide (VIP), it is now considered to be an orphan receptor, in that its endogenous ligand has not been identified. The protein is also a coreceptor for human immunodeficiency viruses (HIV). Translocations involving this gene and HMGA2 on chromosome 12 have been observed in lipomas. [provided by RefSeq]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Wei Y, Zheng X, Huang T, et al. Human embryonic stem cells secrete macrophage migration inhibitory factor: A novel finding. PLoS One. 2023,18(8):e0288281. doi: 10.1371/journal.pone.0288281Read this paper
- Song S, Liu B, Habibie H, et al. D-dopachrome tautomerase contributes to lung epithelial repair via atypical chemokine receptor 3-dependent Akt signaling. EBioMedicine. 2021,68:103412. doi: 10.1016/j.ebiom.2021.103412Read this paper
- Cheng CW, Liao WL, Chen PM, et al. MiR-139 Modulates Cancer Stem Cell Function of Human Breast Cancer through Targeting CXCR4. Cancers (Basel). 2021,13(11). doi: 10.3390/cancers13112582Read this paper
- Wei ST, Huang YC, Hsieh ML, et al. Atypical chemokine receptor ACKR3/CXCR7 controls postnatal vasculogenesis and arterial specification by mesenchymal stem cells via Notch signaling. Cell Death Dis. 2020,11(5):307. doi: 10.1038/s41419-020-2512-2Read this paper
- Xu T, Yu X, Deng J, et al. CXCR7 regulates epileptic seizures by controlling the synaptic activity of hippocampal granule cells. Cell Death Dis. 2019,10(11):825. doi: 10.1038/s41419-019-2052-9Read this paper
- Becker JH, Gao Y, Soucheray M, et al. CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. Cancer Res. 2019,79(17):4439-4452. doi: 10.1158/0008-5472.CAN-19-0024Read this paper
- Li S, Fong KW, Gritsina G, et al. Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2019,79(10):2580-2592. doi: 10.1158/0008-5472.CAN-18-2812Read this paper
- Liu B, Song S, Setroikromo R, et al. CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor. Cancers (Basel). 2019,11(4). doi: 10.3390/cancers11040455Read this paper
- Xu S, Tang J, Wang C, et al. CXCR7 promotes melanoma tumorigenesis via Src kinase signaling. Cell Death Dis. 2019,10(3):191. doi: 10.1038/s41419-019-1442-3Read this paper
- Luo Y, Azad AK, Karanika S, et al. Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer. 2018,142(10):2163-2174. doi: 10.1002/ijc.31237Read this paper






